1. Sweden Stocks

  2. •

    Electronic technology

  3. •

    Electronic equipment/Instruments
SpectraCure AB

SpectraCure AB

0.02
SEK
+0.00
(-0.64%)
-0.08EPS
31.38MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.01
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.04
-0.05
-0.07
-0.05
-0.04
-0.05
-0.06
-0.08
-0.09
-0.07
-0.13
-0.15
-0.08
Free Cash Flow per Basic Share
-0.01
-0.09
-0.26
0.01
-0.08
-0.1
-0.07
-0.09
-0.11
-0.12
-0.2
-0.12
-0.07
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.03
0.12
0.24
0.08
0.26
0.33
0.67
0.6
0.51
0.44
0.36
0.18
0.13
Tangible Book Value per Share
-0.07
0.07
0.15
0.01
0.17
0.2
0.52
0.41
0.3
0.17
0.05
0.02
- -
Basic Weighted Avg Shares
110
110
92
173
238
250
280
294
294
294
178
365
716
Sales/Revenue/Turnover
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-851.79
-738.73
-3,941.99
-3,358.37
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
- -
- -
1
- -
2
2
3
3
3
3
30
30
Net Income, GAAP
-4
-6
-6
-9
-10
-14
-15
-23
-25
-20
-23
-56
-56
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-912.64
-755.89
-3,685.2
-3,358.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
-4
8
13
2
43
49
149
118
82
48
11
6
-3
LT Debt
- -
- -
- -
- -
- -
5
3
2
- -
4
3
- -
6
Total Equity
-3
13
22
13
65
88
197
176
150
130
107
94
94
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-36.24
-48.97
-24.54
-17.92
-10.81
-12.52
-15.57
-14.59
-19.44
-55.97
-48.61

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
3
2
3
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
528
735
735
Market Capitalization
64
50
31

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
16
19
10
Cash, Cash Equivalents & STI
14
17
8
Accounts Receivable, Net
1
1
- -
Inventories
- -
- -
- -
Total Current Liabilities
11
11
13
Payables & Accruals
- -
- -
- -
ST Debt
3
2
3
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.48%
-13.83%
-12.45%
Free Cash Flow
-86.51%
17.49%
19.97%
Net Income, GAAP
30.73%
39.42%
143.78%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.02
-0.02
-0.04
-0.01
-0.13
2025
-0.02
-0.02
-0.07
-0.01
-0.15
2026
-0.01
-0.01
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Johannes Swartling
Full Time Employees
13
Sector
Electronic technology
Industry
Electronic equipment/Instruments
Address
Gasverksgatan 1 Lund SN Sweden 222 29
IPO Date
Jul 1, 2015
Website
spectracure.com
Similar Companies
Advantest Corp. (TSE:6857)
Unusual Machines, Inc. (AMEX:UMAC)
FuelCell Energy, Inc. (NASDAQ:FCEL)
Lasertec Corp. (TSE:6920)
Hitachi Energy India Limited (NSE:POWERINDIA)
Keysight Technologies Inc. (NYSE:KEYS)
Business
SpectraCure AB (publ) specializes in advanced medical technology for cancer treatment, developing a proprietary system that combines laser light sources with photoreactive drugs through interstitial photodynamic therapy (PDT). Central to their approach is the patented IDOSE® software, designed to precisely control laser light dosage for optimal tumor elimination. The company is actively conducting a Phase II clinical study in North America and Europe for recurrent localized prostate cancer, and has initiated a Phase I/II study for primary localized prostate cancer. This innovative system aims to offer a highly precise, individualized, and minimally invasive solution for solid tumors, with future potential for applications in breast, pancreatic, and head and neck cancers. SpectraCure was established in 2003 as a spin-off from Lund University and operates from Lund, Sweden.